Epsilogen, a UK-based biotech developing pan-isotype antibody therapies for use in cancer treatment, has appointed Cristina Oliva as chief medical officer.
The appointment follows the completion of a phase 1 trial for Epsilogen’s lead candidate, Mov18 IgE, which demonstrated early signs of clinical activity while being safe and well tolerated by patients. A phase 1b trial in patients with platinum-resistant ovarian cancer is now underway.
Tim Wilson, CEO of Epsilogen, said: “I believe Cristina’s extensive experience in oncology drug development will be invaluable as we continue to advance MOv18 IgE through phase 1b studies and progress other assets from our unique IgE, IgA and IgG-based therapeutics platforms towards the clinic.”
Cristina is a board-certified oncologist with more than 20 years’ experience across the pharma, biotech and clinical research sectors. Prior to joining Epsilogen, she served as chief medical officer at BerGenBio from 2022. She was previously vice president, Oncology, and head of the Oncology Centre of Excellence at IQVIA, where she also chaired the company’s Global Oncology Scientific Advisory Board.
Cristina commented: “I am thrilled to be joining Epsilogen at such an exciting time in the Company’s growth and look forward to advancing Epsilogen’s assets addressing high unmet medical needs.”